Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics

An intravenous (i.v.) formulation of mycophenolate mofetil (MMF; CellCept(R ), Roche Pharmaceuticals, Inc., Pale Alto, CA) that will enable its adminis tration to patients unable to tolerate oral medication is available. Two se parate studies, an open-labeled pharmacokinetic (PK) study and a double-bli nd safety study, were performed. Within 24 h after transplant, 153 (safety study) and 45 (PK study) first or second renal transplant recipients were s tarted on i.v. MMF 1 g Q12h or placebo (used in the safety study only, 2:1 MMF:placebo): given over 2 h via a dedicated peripheral venous catheter. In the safety study, per os (p.o.) MMF (1g Q12h) or placebo was administered. starting within 72 h after transplant, whereas in the PK study, p.o. MMF w as started on the evening of day 5. Sequential blood samples obtained on st udy days 5 (i.v. MMF) and 6 (p.o. MMF) before and up to 12 h after the AM d ose were analyzed for mycophenolic acid (MPA) and MPA glucuronide (MPAG) co ncentrations by high-performance liquid chromatography. The area under the concentration curve (AUC) was calculated using the linear trapezoidal rule. The MPA AUC(0-12) was higher for i.v. MMF than p.o. MMF (40.8 +/- 11.4 mu g.h/mL vs. 32.9 +/- 15, p < 0.001). There were no other significant PK diff erences for plasma MPA or MPAG. In the safety study (n = 98 i.v. MMF vs. n = 55 placebo), 11 patients (11%, i.v. MMF) and 4 patients (7%, placebo) dis continued their use of the drug because of an adverse event (AE). Overall, AEs were similar between i.v. MMF and placebo. Injection site phlebitis (4% ) and thrombosis (4%) were observed only with i.v. MMF. MMF i.v. 1 g twice daily (b.i.d.) should provide efficacy at least equivalent to p.o. MMF with out increased toxicity, and it provides an acceptable alternative dose form in the immediate period after transplant.